Stocks

Stocks Market News

20 stories
NEWS lse

REG - Stock Exch Notice - Admission to Trading - 24/07/2026

RNS Number : 6516N London Stock Exchange Notice 24 July 2026  NOTICE OF ADMISSION TO TRADING ON THE LONDON STOCK EXCHANGE24/07/2026 - 08:00The following securities are admitted to trading on the LSE with effect from the time and date of this noticeFollowing a Capital Reorganisation this security…

London Stock Exchange en_IN
StocksGB

REG - AIM Volex PLC - Readmission - VOLEX PLC

RNS Number : 6128N AIM 24 July 2026  NOTICE24/07/2026 - 08:00NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIMFollowing a Transfer to the Main Market the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.If you have any queries or…

London Stock Exchange en_IN
ETFsStocksGB
NEWS acceswire

LiberNovo Omni SE, Omni Pro and Maxis Enter Final Week of Early Bird Launch Pricing

HONG KONG, HK / ACCESS Newswire / July 24, 2026 / Seven days is what remains of LiberNovo's 2026 launch pricing. Across the EU and UK, Omni SE, Omni Pro, and the Maxis series hold their early bird prices until July 31, and the window closes there.The whole lineup is built around dynamic ergonomics…

ACCESS Newswire en_IN
StocksCNHKUS
NEWS lse

REG - AIM - AIM Notice - 24/07/2026

RNS Number : 6496N AIM 24 July 2026  NOTICE24/07/2026 - 08:00The London Stock Exchange admits the following securities to trading on AIM:AMENDMENTFollowing a Capital Reorganisation the following security has been amended:These should appear as:If you have any queries or require further informati…

London Stock Exchange en_IN
StocksGB
trading-economics

ASX 200 Ends Week Lower as Tech, Gold Miners Slide

Australia's ASX 200 dropped 67 points, or 0.75%, to finish at 8,772 on Friday, reversing gains from the previous three sessions as weakness spread across tech, consumer durables, non-energy minerals, and healthcare.Sentiment soured after the Trump administration said it would impose new tariffs on…

Trading Economics en_IN
indexStocksAU
modular_finance

First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis

Lund Sweden, July 24, 2026 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the Phase Ib/II clinical study of tasquinimod following an amendment to the study protocol, with increased flexibility in the dosing regimen of tasquinimod. The study evalua…

MFN by Modular Finance en_IN
StocksSE